Journal Article

DKFZ-2025-02481

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Clinical potential of [18F]FET PET in patients with circumscribed astrocytic glioma.

Werner, J.-M. ; Mair, M. J. ; Wollring, M. M. ; Barci, E. ; Stetter, I. ; Puhr, H. C. ; Tscherpel, C. ; Stoffels, G. ; Hainfellner, J. A. ; Berghoff, A. S. ; Sunder-Plassmann, V. ; Widhalm, G. ; Eckert, F. ; Kasprian, G. ; Nakuz, T. S. ; Beck, A. ; Harter, P.DKFZ* ; von Baumgarten, L.DKFZ* ; Thon, N. ; Schönecker, S. ; Forbrig, R. ; Mottaghy, F. M. ; Lohmann, P. ; Fink, G. R. ; Langen, K.-J. ; Galldiks, N. ; Albert, N. L. ; Preusser, M.

2025
Springer-Verl. Heidelberg [u.a.]

Abstract: To investigate the clinical potential of O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) PET imaging in the management of circumscribed astrocytic gliomas (CAG), a rare glioma subtype with limited imaging data.We retrospectively identified adult CAG patients who underwent [18F]FET PET imaging (i) before diagnosis, (ii) at suspected relapse, or (iii) for response assessment at three institutions. Maximum and mean tumor-to-brain ratios (TBRmax, TBRmean) and metabolic tumor volumes were assessed according to the PET RANO 1.0 criteria. Diagnostic performance in differentiating treatment-related changes from tumor relapse was evaluated using ROC analysis and Fisher's exact test.We evaluated 79 [18F]FET PET scans of 42 patients, including nine (21%) with actionable molecular targets. Measurable [18F]FET uptake was observed in 65% of WHO grade 1 and 100% of WHO grade 2 and 3 CAG. TBR values were significantly higher in WHO grade 2 and 3 CAG than in pilocytic astrocytomas (P < 0.01), but showed no difference based on molecular target status (P > 0.05). In 5 of 11 patients (45%), treatment response assessment by PET RANO 1.0 differed from MRI. Treatment-related changes were confirmed in 12 patients (43%). In CAG WHO grades 2 or 3, the accuracy of [18F]FET PET to identify treatment-related changes was 82% using single PET scans and 100% using serial PET imaging (P < 0.05).[18F]FET PET can contribute to clinical management of patients with CAG by detecting measurable disease, differentiating treatment-related changes from tumor progression, and showing potential in treatment response assessment through longitudinal imaging.

Keyword(s): BRAF ; PET RANO 1.0 ; Response assessment ; Treatment-related changes

Note: epub

---

Contributing Institute(s):

1. DKTK Koordinierungsstelle München (MU01)

Research Program(s):

1. 899 - ohne Topic (POF4-899) (POF4-899)

Appears in the scientific report 2025

---

Database coverage:
; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; DEAL Springer ; DEAL Springer ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---